ABIONYX announces a capital increase without preferential subscription rights

ABIONYX Pharma is launching a capital increase of approximately 3.4 million euros through the issue of shares accompanied by share subscription warrants (ABSA). The subscription price is set at 1.37 euros per ABSA. Each subscription warrant allows you to obtain one share to be issued at a price of 3 euros. The exercise period is three years.

This operation aims to strengthen the company's cash flow to support its development in sepsis and in the United States. ORSAY 53 has committed to subscribing to nearly 94% of the issue. A historic shareholder, Mr. Luc Demarre, also declared his intention to subscribe.

The Board of Directors of ABIONYX decided to issue 2,472,000 new securities, representing approximately 7.62% of the capital. The new shares will be admitted to trading on Euronext.